Rise and shine, everyone, another busy day is on the way. The Pharmalot campus, of course, is already humming as the short people depart and we brew our mandatory cup of stimulation. Our flavor today is the aromatic Southern pecan, an old standby. Meanwhile, we are rummaging through all sorts of things in the hunt for interesting stories. For now, here is the usual menu of tidbits. Have a smashing day and do stay in touch …

Novartis (NVS) agreed to pay $2.1 billion to acquire Endocyte (ECYT) in order to gain access to a new treatment being developed for prostate cancer, The Wall Street Journal tells us. Endocyte specializes in so-called radiopharmaceuticals, a new class of drug that carries radioactive substances directly to cancer cells so they can kill tumor cells at close range. Novartis already sells a radiopharmaceutical directed at a rare form of gut cancer, which it acquired last year as part of its $3.9 billion deal for Advanced Accelerator Applications.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy